SG50011A1 - Novel prodrugs for the therapy of tumors and inflammatory disorders - Google Patents

Novel prodrugs for the therapy of tumors and inflammatory disorders

Info

Publication number
SG50011A1
SG50011A1 SG1997000702A SG1997000702A SG50011A1 SG 50011 A1 SG50011 A1 SG 50011A1 SG 1997000702 A SG1997000702 A SG 1997000702A SG 1997000702 A SG1997000702 A SG 1997000702A SG 50011 A1 SG50011 A1 SG 50011A1
Authority
SG
Singapore
Prior art keywords
alkyl
alkylamino
glycosyl
tumors
therapy
Prior art date
Application number
SG1997000702A
Other languages
English (en)
Inventor
Klaus Bosslet
Joerg Czech
Manfred Gerken
Rainer Straub
Claude Monneret
Jean-Claude Florent
Frederic Schmidt
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG50011(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of SG50011A1 publication Critical patent/SG50011A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG1997000702A 1996-03-12 1997-03-12 Novel prodrugs for the therapy of tumors and inflammatory disorders SG50011A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (1)

Publication Number Publication Date
SG50011A1 true SG50011A1 (en) 1998-06-15

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1997000702A SG50011A1 (en) 1996-03-12 1997-03-12 Novel prodrugs for the therapy of tumors and inflammatory disorders

Country Status (24)

Country Link
US (1) US5935995A (hu)
EP (1) EP0795334B1 (hu)
JP (1) JP4392065B2 (hu)
KR (1) KR100466467B1 (hu)
CN (1) CN1168733C (hu)
AT (1) ATE316799T1 (hu)
AU (1) AU708202B2 (hu)
BG (1) BG61900B1 (hu)
BR (1) BRPI9701248B1 (hu)
CA (1) CA2199664C (hu)
CZ (1) CZ297994B6 (hu)
DE (1) DE59712561D1 (hu)
DK (1) DK0795334T3 (hu)
ES (1) ES2257756T3 (hu)
HU (1) HU228764B1 (hu)
NO (1) NO320322B1 (hu)
NZ (1) NZ314368A (hu)
PL (1) PL189604B1 (hu)
RO (1) RO120951B1 (hu)
RU (1) RU2191021C2 (hu)
SG (1) SG50011A1 (hu)
SI (1) SI0795334T1 (hu)
TR (1) TR199700178A2 (hu)
UA (1) UA50719C2 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
JP4812167B2 (ja) 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
EP1465488A4 (en) 2001-08-30 2007-04-18 Chemocentryx Inc ARYLAMINES AS INHIBITORS OF THE BINDING OF CHEMOKINE A US28
CN1671724A (zh) * 2002-06-20 2005-09-21 日本水产株式会社 前药、其作为医药的应用及其制法
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2006038070A2 (en) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
BRPI0809999A2 (pt) * 2007-04-06 2014-10-14 Ziopharm Oncology Inc Sais de mostarda de isofosforamida e análogos da mesma
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
NZ598144A (en) * 2009-09-02 2014-01-31 Auckland Uniservices Ltd Kinase inhibitors, prodrug forms thereof and their use in therapy
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ, インク. ペプチド基を含む複合体及びそれに関連する方法
JP6949732B2 (ja) 2015-11-25 2021-10-13 レゴケム バイオサイエンシズ, インク.Legochem Biosciences, Inc. 自壊性基を含む複合体及びそれに関連した方法
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
AU2019266406A1 (en) 2018-05-09 2020-11-26 Ligachem Biosciences Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
CA2025899A1 (en) * 1989-01-23 1990-07-24 Reinhard Bredehorst Site specific in-vivo activation of therapeutic drugs
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5494911A (en) * 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0538799B1 (en) * 1991-10-25 1995-03-15 TUNGSRAM Részvénytársaság Single-capped low-pressure discharge lamp
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
HU9700579D0 (en) 1997-04-28
CZ297994B6 (cs) 2007-05-16
BRPI9701248B1 (pt) 2022-01-18
ES2257756T3 (es) 2006-08-01
RO120951B1 (ro) 2006-10-30
HUP9700579A2 (en) 1997-12-29
HU228764B1 (en) 2013-05-28
MX9701832A (es) 1998-07-31
US5935995A (en) 1999-08-10
RU2191021C2 (ru) 2002-10-20
KR970065550A (ko) 1997-10-13
PL318878A1 (en) 1997-09-15
TR199700178A2 (tr) 1997-09-21
CA2199664C (en) 2008-05-20
CA2199664A1 (en) 1997-09-12
CN1168733C (zh) 2004-09-29
DK0795334T3 (da) 2006-06-06
EP0795334A2 (de) 1997-09-17
UA50719C2 (uk) 2002-11-15
BG61900B1 (bg) 1998-09-30
EP0795334B1 (de) 2006-02-01
EP0795334A3 (de) 1997-09-24
AU1620597A (en) 1997-09-18
NZ314368A (en) 1998-10-28
HUP9700579A3 (en) 1999-05-28
NO971116L (no) 1997-09-15
CN1163895A (zh) 1997-11-05
BG101290A (en) 1997-09-30
DE59712561D1 (de) 2006-04-13
BR9701248A8 (pt) 2013-06-18
JP4392065B2 (ja) 2009-12-24
NO320322B1 (no) 2005-11-21
NO971116D0 (no) 1997-03-11
ATE316799T1 (de) 2006-02-15
KR100466467B1 (ko) 2005-06-29
CZ74297A3 (en) 1997-09-17
PL189604B1 (pl) 2005-08-31
JPH101495A (ja) 1998-01-06
SI0795334T1 (sl) 2006-06-30
AU708202B2 (en) 1999-07-29
BR9701248A (pt) 1999-10-13

Similar Documents

Publication Publication Date Title
SG50011A1 (en) Novel prodrugs for the therapy of tumors and inflammatory disorders
ATE51231T1 (de) Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als antiallergische mittel.
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
ATE17715T1 (de) N-phenyl-benzamid-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel.
IE892189L (en) Derivatives of (aza) naphthalenesultam, their preparation¹and compositions containing them
SE9603283D0 (sv) New compounds
BR1100061A (pt) Composto, processo para a preparação do mesmo, composição e uso dos mesmos
ATE165095T1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE82969T1 (de) 6-phenyl-3-piperazinylalkyl-1h,3h-pyrimidindion 2,4-derivate, deren herstellung und verwendung als heilmittel.
ATE232386T1 (de) Neue endiyn-chinonimine und verfahren zu deren herstellung und verwendung
ATE188217T1 (de) 1,2,3,4,10,14b-hexahydrodibenzo-c,f)pyrazino-1, - a)azepino-derivate
DK540684A (da) Benzoquinoliziner
ATE281452T1 (de) 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
FI860145A0 (fi) Herbicider av typ n-(fosfonometylglycyl)sulfonylaminer.
GR3024388T3 (en) 2-phenyl-and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties
TR199901484T2 (xx) 2-Amino-2-imidazolin, guanidin ve 2-amino-3,4,5,6-tetrahidropirimidin t�revleri haz�rlama i�lemi.
DE69711506D1 (de) Methylsulfomycin 1, Verfahren zu dessen Herstellung und Verwendung
DE59712054D1 (de) 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
ATE53839T1 (de) 2,3-dihydro-3-phenyl-benzofuran-2-onacetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES2055155T3 (es) Procedimiento para la obtencion de aciloxiacetidinonas opticamente activas.
HUP0101046A2 (hu) Amiloidózis kezelésére alkalmazható amino-antraciklinon-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP9902606A2 (hu) Mátrix metalloproteináz inhibitorok